Similarly, calretinin showed strong immunoreactivity in normal and metformin-treated groups (Fig. 9A and B), decreased in the AD group (p < 0.0001), and then increased after metformin treatment (p = 0.0019) compared to AD rats (Fig. 9C and D). This evidence concerns the gene CALB2 and Alzheimer disease.